Cantor Fitzgerald Forecasts Lower Earnings for Avita Medical

Avita Medical Inc. (NASDAQ:RCEL) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Avita Medical in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($1.16) per share for the year, down from their previous estimate of ($0.99). The consensus estimate for Avita Medical’s current full-year earnings is ($0.95) per share. Cantor Fitzgerald also issued estimates for Avita Medical’s FY2026 earnings at ($0.27) EPS.

RCEL has been the subject of several other research reports. Lake Street Capital decreased their target price on Avita Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Wall Street Zen lowered Avita Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. D. Boral Capital cut their price target on Avita Medical from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, BTIG Research lowered Avita Medical from a “neutral” rating to a “sell” rating and set a $3.00 price target on the stock. in a report on Friday, August 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $12.40.

Avita Medical Trading Down 2.9%

NASDAQ RCEL opened at $5.63 on Friday. The business has a 50 day simple moving average of $5.46 and a 200 day simple moving average of $7.40. Avita Medical has a one year low of $3.60 and a one year high of $14.16. The stock has a market capitalization of $149.87 million, a P/E ratio of -2.86 and a beta of 1.63. The company has a debt-to-equity ratio of 9.39, a current ratio of 0.58 and a quick ratio of 1.72.

Avita Medical (NASDAQ:RCEL) last released its earnings results on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.12). Avita Medical had a negative return on equity of 1,272.91% and a negative net margin of 68.87%. The business had revenue of $18.42 million for the quarter, compared to analyst estimates of $34.27 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RCEL. Vanguard Group Inc. lifted its holdings in shares of Avita Medical by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 1,423,439 shares of the company’s stock valued at $18,220,000 after purchasing an additional 5,767 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Avita Medical by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 597,595 shares of the company’s stock valued at $7,650,000 after purchasing an additional 3,159 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Avita Medical by 5.7% in the fourth quarter. Northern Trust Corp now owns 228,720 shares of the company’s stock valued at $2,928,000 after purchasing an additional 12,253 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Avita Medical in the first quarter valued at approximately $799,000. Finally, Jane Street Group LLC lifted its holdings in shares of Avita Medical by 36.1% in the second quarter. Jane Street Group LLC now owns 86,730 shares of the company’s stock valued at $459,000 after purchasing an additional 22,986 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.

About Avita Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.